TerminatedEUCTR 2011-004845-42

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)

This historical record does not confirm current site availability.

Historical research recordMultiple countries

The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Czechia · Poland and 1 more location
Study phase: Phase 2

Get this study by email

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed

Recruitment status: Terminated
Enrollment listed in the registry: 270
Sponsor: Amgen Inc.
Sponsor type: Other organization
Study type: Drug
Intervention type: Drug
Study phase: Phase 2
Locations: United Kingdom, Czechia, Poland
Age range: Not clearly listed
Official registry ID: EUCTR 2011-004845-42
Official title: Show the full official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Add-on AMG 747 on Schizophrenia Negative Symptoms (Study 165)

Recruitment & locations

Terminated

Czechia · Poland · United Kingdom

Registry details

Historical country statuses

Czechia — Prematurely Ended
United Kingdom — Prematurely Ended
Poland — Prematurely Ended

Interested in joining this study?

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Amgen Inc.

Is this study still recruiting?

The historical registry lists this study as terminated.

Want to explore more studies?

Explore studies